1,262 results on '"Fiedler, Walter"'
Search Results
2. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia
3. Abdominal emergency surgery in patients with hematological malignancies: a retrospective single-center analysis
4. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
5. Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
6. Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy
7. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial
8. Regulation of coagulation activation in newly diagnosed AML by the heme enzyme myeloperoxidase
9. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
10. The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia
11. Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin
12. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL
13. Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy
14. Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19
15. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations
16. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
17. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial
18. Newly diagnosed isolated myeloid sarcoma–paired NGS panel analysis of extramedullary tumor and bone marrow
19. Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy
20. Case Report of a DDX41 Germline Mutation in a Family with Multiple Relatives Suffering from Leukemia
21. Broadening the horizon: potential applications of CAR-T cells beyond current indications
22. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
23. Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza
24. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
25. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial
26. Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy
27. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy
28. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
29. Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia.
30. Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro
31. The prognostic impact of lymphoma perforation in patients with primary gastrointestinal lymphoma – a single-center analysis
32. S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN
33. S114: OUTCOME OF OLDER PATIENTS (>55 YRS) WITH NEWLY DIAGNOSED PH/BCR:ABL POSITIVE ALL PROSPECTIVELY TREATED ACCORDING TO PEDIATRIC-BASED, AGE-ADAPTED GMALL PROTOCOLS
34. P355: FAVORABLE OUTCOME OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH IMATINIB, DOSE-REDUCED INDUCTION FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION –RESULTS FROM THE GMALL TRIAL 08/13
35. P510: PREDICTORS OF RESPONSE AND OUTCOME IN PATIENTS WITH REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA RECEIVING VENETOCLAX WITH NON-INTENSIVE CHEMOTHERAPY
36. AML-440 Prognosis of Molecularly-Defined Secondary Acute Myeloid Leukemia Patients
37. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
38. Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours
39. Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas
40. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
41. Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer
42. Cortisol facilitates the immune escape of human acute myeloid leukemia cells by inducing latrophilin 1 expression
43. Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
44. The Clinical Significance of CD73 in Cancer
45. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
46. An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia
47. Case Report of a DDX41 Germline Mutation in a Family with Multiple Relatives Suffering from Leukemia.
48. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option
49. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial
50. A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.